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Macrolides have both immunomodulatory and antibacterial effects. We report 3 cases 
of primary immune thrombocytopenia (ITP) patients who were successfully treated with 
macrolides, irrespective of Helicobacter pylori (H. pylori) infection status. Case 1, an 
88-year-old woman who was an H. pylori-positive ITP patient, was treated with clari-
thromycin (CAM). CAM was effective temporarily. As an alternative to CAM, she was suc-
cessfully treated with erythromycin (EM) for more than 7 months. Case 2, a 61-year-old 
man who was an H. pylori-negative ITP patient, was unsuccessfully treated with CAM 
but successfully treated with EM. Case 3, a 75-year-old woman who was a H. pylori-neg-
ative ITP patient, was treated with CAM. CAM was effective temporarily. After approx-
imately 6 months, she was treated with EM for a common cold, and her platelet count 
increased rapidly. Based on these findings, macrolide treatment was effective for ITP. The 
effectiveness of macrolides might suggest immunomodulatory effects as well as anti-
bacterial effects for H. pylori.
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INTRODUCTION
  Macrolides have both immunomodulatory effects and anti-
bacterial effects against organisms such as Helicobacter pylori 
(H. pylori) [1-3]. We have already reported 3 cases of idio-
pathic thrombocytic purpura (ITP), also known as primary 
immune thrombocytopenia, which show increased platelet 
counts following clarithromycin (CAM) treatment, irre-
spective of H. pylori infection status [4]. ITP is an auto-
immune disease induced by autoantibodies against platelets. 
In our previous report, the fact that platelet count normalized 
following CAM treatment suggested immunomodulatory 
effects of macrolides. Erythromycin (EM) was the first mac-
rolide to be developed and showed poor activity against 
bacteria compared with new macrolides such as CAM, which 
has been developed to supersede EM［3]. We report 3 cases 
of ITP that were successfully treated with macrolides. In 
these cases, EM was considered more effective than CAM.
CASE REPORT
1. Case 1
　An 88-year-old woman who had been suffering from ITP 
for several years was admitted for resection of a small tumor 
of the tongue. Platelet count remained at a level of around 
20×10
9/L. Initial laboratory data showed reduced platelet 
counts (24×10
9/L). The patient was referred to our depart-
ment for management of platelet count, which needed to 
be increased to about 50×10
9/L before tumor resection. 
Although a positive result was obtained for anti-H. pylori 
IgG antibodies, the patient could not be treated by eradication 
therapy because of an allergy to penicillins. As the patient 
was suffering from osteoporosis and refused platelet trans-
fusion, she was treated using CAM without prednisolone 
(PSL). The clinical course is shown in Fig. 1. CAM was 
given at 400 mg/day. Platelet count had increased to 42×10
9/L 
by 5 days after CAM treatment and then resection was safely 
performed. Little bleeding was seen during and after resec-
tion. After resection, the platelet count had decreased to 
28×10
9/L despite CAM treatment. The patient was treated 
with EM at a dose of 600 mg/day as an alternative to CAM. Korean J Hematol 2011;46:139-42.
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Fig. 1. Change of platelet counts following clarithromycin (CAM) and 
erythromycin (EM) treatments. Fig. 2. Change of platelet counts following prednisolone (PSL), methyl-
prednisolone (mPSL), CAM, and EM treatments.
Fig. 3. Change of platelet counts following CAM and EM treatments.
The platelet count had increased to 35×10
9/L by 7 days after 
starting EM treatment. After the patient was discharged, 
the platelet count remained at about 34-39×10
9/L. We tried 
stopping EM prescriptions for 1 month, but the platelet count 
decreased to 26×10
9/L. Re-treatment with CAM did not im-
prove the platelet count, so she was re-treated using EM 
a t  a  d o s e  o f  8 0 0  m g / d a y  i n s t e a d  o f  C A M .  A f t e r  1  w e e k ,  
platelet count increased from 21×10
9/L to 31×10
9/L. The dose 
of EM was therefore reduced to 600 mg/day. By the end 
of the observation period, platelet count had increased to 
44×10
9/L.
2. Case 2
　A 61-year-old man was referred with purpura, which had 
appeared several months before. Initial laboratory data 
showed a reduced platelet count (14×10
9/L), so he was admit-
ted for further investigation. Anti-nuclear antibody was pos-
itive (titer 1：640, speckled). Testing for anti-dsDNA anti-
body, anti-SSA antibody, anti-RNP antibody, anti-Sm anti-
body, and anti-Topo I antibody all yielded negative results, 
as did testing for anti-H. pylori IgG antibody. A bone marrow 
specimen revealed hyperplasia of normal megakaryocytes. 
Neither articular swelling nor skin rash suggestive of collagen 
disease was present. Based on clinical and laboratory findings, 
ITP was diagnosed. The clinical course is shown in Fig. 
2. PSL was given at 60 mg/day for 4 days, but the platelet 
count still decreased to 6×10
9/L. Methylprednisolone pulse 
therapy was therefore performed and PSL reduced to 30 
mg/day because of hyperglycemia. By 1 week after pulse 
therapy, platelet count had only increased to 20×10
9/L. The 
patient was treated with CAM at a dose of 400 mg/day 
after obtaining informed consent. About 4 weeks after treat-
ment for ITP, platelet count did not increase and remained 
at 17×10
9/L. The patient was therefore administered EM 
at 600 mg/day as an alternative to CAM. After 2 weeks, 
platelet count increased to 77×10
9/L and oral PSL could be 
gradually tapered. By the end of the observation period, 
platelet count increased to 208×10
9/L.
3. Case 3
　A 75-year-old woman suffering from ITP was admitted 
with a gradual decrease in platelet count. Prior to admission, 
platelet count had remained at a level of around 40×10
9/L. 
Laboratory data on admission showed reduced platelet counts 
(18×10
9/L). Anti-H. pylori IgG antibody and urea breath Korean J Hematol 2011;46:139-42.
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tests were negative. The clinical course is shown in Fig. 
3. CAM was given at 800 mg/day after informed consent 
was obtained. Platelet count had rapidly increased to 
131×10
9/L by 7 days after CAM treatment. However, after 
1 month, platelet count had decreased to 40×10
9/L despite 
CAM treatment. Because liver dysfunction occurred, we 
stopped prescribing CAM. After the patient was discharged, 
the platelet count remained at about 35-50×10
9/L without 
medication. The patient was treated with EM at a dose of 
600 mg/day for a common cold. After 1 week, platelet count 
had increased from 43×10
9/L to 97×10
9/L. Because the patient 
recovered from the cold, EM prescription was stopped. After 
1 month, the platelet count had decreased to 41×10
9/L. By 
the end of the observation period, platelet count had re-
mained at a level of around 40×10
9/L without medication. 
DISCUSSION
　In Case 1, CAM treatment appeared to be effective tempo-
rarily. Re-treatment with CAM proved ineffective. Although 
the platelet count remained at only about 31-44×10
9/L with 
EM treatment, including re-treatment, EM was considered 
more effective than CAM.
　ITP is an autoimmune disease induced by autoantibodies 
against platelets. Recent studies have suggested that ITP pa-
tients infected with H. pylori can be successfully treated 
by eradication (proton pump inhibitors, amoxicillin, and 
CAM) [5, 6]. In Case 1, platelet counts might have increased 
as a result of the antibacterial effects of macrolides against 
H. pylori. However, the higher effectiveness of EM compared 
with CAM could not be explained, as CAM generally shows 
superior activity against H. pylori compared with EM [4]. 
This effectiveness might suggest the superiority of EM to 
CAM with regard to immunomodulatory effects independent 
of infection. Possibly this decrease in platelet count, despite 
CAM treatment, might suggest side effects of CAM.
　In general, platelet count increases within 4 weeks of 
starting PSL treatment. Similarly, platelet count increases 
3-5 days after starting methylprednisolone pulse therapy. 
Steroid therapy in Case 2 thus appeared largely ineffective. 
　As CAM treatment only maintained platelet count, CAM 
was not considered sufficiently effective in Case 2. However, 
EM was clearly effective, as could be seen by gradual im-
provements in platelet counts.
　In Case 2, EM treatment was effective for an H. pylori-neg-
ative ITP patient. The pathogenesis of H. pylori-negative 
ITP is thought to involve autoimmunity derived from 
EM-sensitive bacteria other than H. pylori, or immunological 
dysregulation independent of infection. 
　In Case 3, CAM treatment appeared to be effective 
temporarily. The cause of the decrease in platelet count, 
despite CAM treatment, might suggest that CAM has side 
effects, as in Case 1.
The fact that EM treatment for a common cold increased 
the platelet count also suggests the effectiveness of EM for 
ITP. 
　In our previous report and in this report, the fact that 
platelet count increased following macrolide treatment sug-
gests immunomodulatory effects of macrolides. 
　Immunomodulatory effects from macrolide antibiotics 
might be obtained by the eradication of bacteria or by modu-
lation of the immune system involving the mucosa on which 
commensal bacteria reside [7]. Alternatively, these effects 
might be pharmacological functions of the macrolide itself, 
independent of antibiotic effects. 
　Apart from antibacterial effects, macrolides have effects 
on neutrophil function (decreased oxidant production, apop-
tosis) and on the production of cytokines involved in the 
inflammation cascade (decreased production of IL-1, IL-6, 
IL-8, and TNF and increased production of IL-10 and, possi-
bly, IL-4) [1]. With regard to T lymphocytes, EM and its 
derivatives inhibit T lymphocyte proliferation and induce 
T lymphocyte apoptosis [2]. 
　Apart from these immunomodulatory effects, macrolides 
have steroid-sparing effects via their influence on cortico-
steroid metabolism [8]. In Case 2, steroid-sparing effects 
might increase the platelet count.
　EM was the first macrolide to be developed. New macro-
lides such as CAM and azithromycin have since been devel-
oped to supersede EM. CAM is a semisynthetic macrolide 
antibiotic, chemically identified as 6-0-methylerythromycin 
A [9]. A close analogy exists between CAM and EM. However, 
in the present report, although only 3 cases were studied, 
macrolides proved effective for ITP, as in our previous report, 
and EM was considered more effective than CAM.
　As a slight structural change is thought to be advantageous 
to CAM in terms of antibacterial effects, similarly, a slight 
change may be advantageous to EM for providing immuno-
modulatory effects.
　For the purpose of clarifying which macrolide is more 
effective, crossover tests between EM and CAM are needed 
in the future.
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